logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
BackJournal Details
Future Oncology cover

Future Oncology

IF2.6
Papers5237
Citations7830
Journal Papers 5616
Publication Date
delete
Gedatolisib for the treatment of hormone receptor-positive/HER2-negative advanced breast cancer: a European perspective
deleteFuture Oncology
IF2.6
delete2026-10-05
delete0
PREAI
deleteLetizia Matera; Julian David Etessami; Carmine Valenza; Giuseppe Curigliano
deleteShare
deleteSave
Post-ASCO 2026: resident-led highlights of the most clinically relevant studies in genitourinary oncology
deleteFuture Oncology
IF2.6
delete2026-10-03
delete0
PREAI
deleteMartina Izzi; Kristian Shtembari; Stefano Specchiarello; Chiara Calandrelli; Silvia Mancini; Marinella Micol Mela; Virginia Rossi; Roberta Giorgione; Daniele Rossini; Serena Pillozzi; Lorenzo Antonuzzo; Giandomenico Roviello
deleteShare
deleteSave
SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy
deleteFuture Oncology
IF2.6
delete2026-10-01
delete0
deleteOAAI
deleteJamie Chaft; Jay M. Lee; Suresh Senan; Joel W. Neal; Ernest Nadal; Marcelo V. Negrao; Sanjay Popat; Marina C. Garassino; Jhanelle E. Gray; Se-Hoon Lee; Julien Mazieres; Michael Thomas; Martin Benes; Hui Liu; Jian Liu; Qinli Lily Ma; Grace Segall; Tarun Puri; Yi-Long Wu
deleteShare
deleteSave
DUBHE-H-308 study protocol: rationale and adaptive design of a randomized, open-label, seamless phaseII/III trial of iparomlimab and tuvonralimab (QL1706)-based regimens versus sintilimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma
deleteFuture Oncology
IF2.6
delete2026-10-01
delete0
PREAI
deleteFan Yang; Weikang Tao; Zihang Zhong; Jia Fan; Hao Yu; Shukui Qin
deleteShare
deleteSave
Plain language summary of the J-TAIL-2 study results: a study of Japanese patients with extensive-stage small cell lung cancer that followed their treatment with atezolizumab plus chemotherapy over time
deleteFuture Oncology
IF2.6
delete2026-10-01
delete0
deleteOAAI
deleteEisaku Miyauchi; Makoto Nishio; Kadoaki Ohashi; Atsushi Osoegawa; Eiki Kikuchi; Hideharu Kimura; Yasushi Goto; Junichi Shimizu; Hiroshige Yoshioka; Ichiro Yoshino; Toshihiro Misumi; Nobuyuki Katakami; Masahide Oki; Takashi Kijima; Kenichi Chikamori; Kazumi Nishino; Takuma Arai; Kenichiro Ieda; Akihiko Gemma
deleteShare
deleteSave
STELLAR-311: a randomized phase II/III study of zanzalintinib versus everolimus in advanced neuroendocrine tumors
deleteFuture Oncology
IF2.6
delete2026-09-28
delete0
deleteOAAI
deleteJennifer A. Chan; Jonathan R. Strosberg; Changhoon Yoo; Simron Singh; Huang Huang; Manika Goel; Christian Scheffold; Jaume Capdevila
deleteShare
deleteSave
Infections in MonumenTAL-1: a plain language summary of talquetamab treatment for relapsed/refractory multiple myeloma
deleteFuture Oncology
IF2.6
delete2026-09-28
delete0
deleteOAAI
deleteCarolina Schinke; Paula Rodríguez-Otero; Niels W.C.J. van de Donk; Brea Lipe; Noa Lavi; Leo Rasche; Diana Cortes-Selva; Tara Masterson; Sheetal Khedkar; Jaszianne Tolbert; Colleen Kane; Ibrahim Saber; Christoph Heuck; Ajai Chari
deleteShare
deleteSave
Is neoadjuvant therapy redefining the surgeon’s role in melanoma?
deleteFuture Oncology
IF2.6
delete2026-09-24
delete0
deleteOAAI
deleteRoger Olofsson Bagge
deleteShare
deleteSave
Review of evidence and future directions following the TUBA study: a long-term prospective preference study comparing risk-reducing salpingectomy with delayed oophorectomy to salpingo-oophorectomy
deleteFuture Oncology
IF2.6
delete2026-09-23
delete0
deleteOAAI
deleteFabienne C. Lof; Tamar A. Gootzen; C. Marleen Kets; Marleen M.H.J. van Gelder; Majke H.D. van Bommel; Michiel Simons; Rosella P.M.G. Hermens; Miranda P. Steenbeek; Joanne A. de Hullu
deleteShare
deleteSave
Beyond survival: advancing psycho-oncology research on fear of recurrence or progression
deleteFuture Oncology
IF2.6
delete2026-09-23
delete0
deleteOAAI
deleteAnne Brédart; Pauline Bugeon; Céline Bodelet; Morgan Dondin; Anita Muller; Sébastien Simard; Sylvie Dolbeault
deleteShare
deleteSave
A patient’s experience with follicular lymphoma from diagnosis to cure: the life-changing impact of CAR T-cell therapy
deleteFuture Oncology
IF2.6
delete2026-09-22
delete0
deleteOAAI
deleteLaurie Adami
deleteShare
deleteSave
First-line management of unresectable hepatocellular carcinoma: clinical perspectives from the CheckMate 9DW study
deleteFuture Oncology
IF2.6
delete2026-09-22
delete0
deleteOAAI
deleteBruno Sangro; Peter Galle; David Tai; Thomas Yau
deleteShare
deleteSave
Plain language summary of the RELATIVITY-098 study results: nivolumab plus relatlimab given after melanoma is removed by surgery
deleteFuture Oncology
IF2.6
delete2026-09-22
delete0
deleteOAAI
deleteGeorgina V. Long; Charlie Garnett-Benson; Sonia Dolfi; Paolo A. Ascierto; Jun Guo; Ahmad A. Tarhini; Sunandana Chandra; Eva Muñoz-Couselo; Michele Del Vecchio; Andreia Cristina de Melo; Margaret Callahan; Helen Gogas; Reinhard Dummer; Dirk Schadendorf; Peter Koelblinger; Gaelle Quereux; Ioannis Thomas; Jia Xin Yu; Andrew Fisher; Bonnie Wang; Patrick Djidel; Armand Chouzy; Mark Semaan; Bohang Chen; Alicia M. Y. Cheong; Hussein A. Tawbi
deleteShare
deleteSave
The role of contrast enhanced ct plus pan-immune-inflammation value in predicting outcomes of hepatocellular carcinoma after hepatectomy
deleteFuture Oncology
IF2.6
delete2026-09-21
delete0
PREAI
deleteLu He; Chunhong Hu
deleteShare
deleteSave
Translating avelumab maintenance into clinical practice: nationwide outcomes in Czech patients with advanced or metastatic urothelial carcinoma
deleteFuture Oncology
IF2.6
delete2026-09-20
delete0
deleteOAAI
deleteAnezka Zemankova; Bohuslav Melichar; Michal Eid; Alexandr Poprach; Jindrich Kopecky; Tomas Buchler; Darja Sustrova; Sarka Stuhlova; Jan Dvorak; Zuzana Donatova; Pavel Vlcek; Katerina Zychackova; Jana Katolicka; Tomas Blazek; David Vrana; Ondrej Fiala; Petra Majkova; Adam Cepa; Hana Studentova
deleteShare
deleteSave
Efficacy of anlotinib plus immune checkpoint inhibitors in soft-tissue sarcoma: systematic review and meta-analysis
deleteFuture Oncology
IF2.6
delete2026-09-19
delete0
PREAI
deleteAhmed Farid Gadelmawla; Ahmed A. Abo Elnaga; Abdullah Faisal Albukhari; Raseel B. Almutairi; Basmah Alamri; Sami Mohammed Alhuways; Fatemah Althaher; Flwah Aloufi; Abdullah Mohammed A. Alotaibi; Abdullah Alali; Ali Almatri; Hamad Althawadi; Abdullah Altamimi
deleteShare
deleteSave
MH-Penile-002: a phase II, prospective, single-arm trial of neoadjuvant anti-EGFR antibody-drug conjugate plus PD-1 inhibitor in penile cancer with challenging penile preservation or regional lymph node metastasis
deleteFuture Oncology
IF2.6
delete2026-09-18
delete0
PREAI
deleteJia-Yao Wang; Yan-Xiang Shao; Li-Li Yang; Hong-Shuai Li; Jia-Qi Liu; Rui-Zhi Liu; Shuang Zhang; Xiang Li; Ji-Yan Liu
deleteShare
deleteSave
A UK Delphi consensus study on the definition and management of advanced cutaneous squamous cell carcinoma
deleteFuture Oncology
IF2.6
delete2026-09-17
delete0
deleteOAAI
deleteAmarnath Challapalli; Amer Durrani; Grant Stewart; Heather Shaw; John Lear; Kate Fife; Kim Peate; Miranda Payne; Ricky Frazer; Jonathan Pollock
deleteShare
deleteSave
Re: prognostic value of the glucose-to-lymphocyte ratio in surgically treated endometrial cancer
deleteFuture Oncology
IF2.6
delete2026-09-16
delete0
deleteOAAI
deleteHavva Beyaz; Yılmaz Tezcan
deleteShare
deleteSave
Plain language summary of the ZUMA-5 study of axicabtagene ciloleucel for people with relapsed or refractory slow-growing non-Hodgkin lymphoma
deleteFuture Oncology
IF2.6
delete2026-09-16
delete0
deleteOAAI
deleteSattva S. Neelapu; Olga Nikolajeva; Caron A. Jacobson
deleteShare
deleteSave